our morning, you, on today. Stevens, I our you today's Areglado, everyone, am call and Thank President. Jeremy, for good Stacey CFO; joined thank and joining us by Scott
provide an current specific our plans. to the more and with on have today opportunity update pleased growth are and progress, speak future We both and financial to strategic on details present performance you
continuing to AI emphasize the goal detection AI further In of breast our our technology capability image for leader enabling iCAD into beyond our unique to detection, expanding long-term AI. clinical it company's like in transform I'd reiterate Detection, cancer to iCAD. begin, vision reflects as I clinical Cancer To has AI AI solutions. the potential evolve the clear
are that appropriately the radiation executing my as are tracking let's remarks progress. as noting vision tailwinds and focus our promising in we an we progress stated business in today IORT, guidance making into and await I right we the and will are results or reimbursement In get on CMS. above. With our introduction, there that further carefully therapy intraoperative XXXX on from clarity
with success are on digital start update to Let's deep-learning detection AI, momentum software with the solution we our an ProFound breast continuing and tomosynthesis. cancer XD for experience latest
We are approval. following the quarters full now three FDA AI, commercial into December launch ProFound XXXX U.S. of the
of: two, our three, reading As tomo XX% and XD their win fewer ProFound detecting more a reading triple patient patients, for cancers; callbacks; unnecessary offers to when compared reminder, reduction one, customers alone. and time in the AI images a over
marketplace these benefits are our sales results in by being Importantly, achievements. important validated other and the
ProFound basis, the detection license further overview market quarter. our revenue Stacy some XXXX AI, provide period the an granularity for will impressive will pleased grew sequential the and provide XX% sales second landscape the On year-over-year. important in business, the as a I of quarter XX% Of grew high-level detection revenue of to same XXXX. report that XX% detection third in growth software a the increased XX% over I'm color. of and to compared
over the first up of the detection months year. was year, Over nine revenue period the XX% same last
metrics. With our end driving growth to continue at of strategy. our executing XXXX of $XX.X on cash and strength. our quarter now well We improving million remain discuss with from ended million also cash in equivalents some me business $XX.X details the I grow let third and a of should that compared to as the position that, positioned the operational continue to we financial add financial
Radiology, others which included and third large-scale in We of accounts growing larger still We third this with first In the all-Hologic similarly transactions. our quarter, a number a close quarter is the Jefferson and in remain sizable other to are sales beginning closed our large compete account. for several account pipeline.
cycles. issues with accounts more licenses longer privacy sites introduce multiple times It have which is multiple important larger associated intrinsically note to of accounts and longer. the and longer and These that take sales security implementation
actively We expect as we are continue to this trend larger now accounts. penetrating
than Also processes, contributing and at These bureaucratic they are sales increased for-profit similar so or more a cycle to interest from modest-sized lengthening deals more clinical to tend sites. we a take university have approval seeing locations institutions. the to longer is academic close would
problems of areas academic Of of we course, have for from our significant ecosystem. increased to new the indicative are continue and demand the quality to interest in expanded growing uptake care experience market health ProFound institutions the with involvement and are and AI larger accounts and
Based initial thoughtfully success we in add capabilities. strengthen direct reps or to with sales our U.S. on our to the continue to commercial the ProFound, rather U.S. --
the In addition, XXXX half of areas accelerating success coverage and/or the ahead. we the have quarters in we to where saw most sales success certain in realigned territories in intensify first see those
while possible I an in very there bullish, that in XXXX. U.S. the anticipated competitive believe now should entry note that we of remains likelihood for ProFound AI our is outlook seeing a
a of commercial We be year-end, the expect or are competitors confident our we and calibrate we any to expand. and that our trade our robust, year and remain will better marketplace, in show, potential the we'll in will America Society approach By RSNA competitive further ahead edge Radiological differentiation this of full innovation QX big as North December.
analysis us X,XXX and iCAD advantage. software over commercial experience Today, clinical accounts base X base, significant installed of This an and X,XXX systems. installed has a acumen with along gives of installed image decades
facing decisions headwinds mindful, entry. extend a the moderate competitive purchasing customer cycles with of however, software-focused that potential have as are We
We monitoring carefully this. are
XXXX. for effort extend development our expected in available June reasons result technology next-generation our to financing will be AI in was core further the of and algorithm the advantage. accelerate well One our to designed underway This is that technological commercially next-generation to XXXX of
more largest of collection images being have world's or the full AI iCAD ProFound breast With for approaching X,XXX AI from Our noting ready XD we access vendors. installations installed and an ProFound multiple enormous release year an of AI systems imaging XXX% approaching year that next-generation data repository. It's collected XXXX tomo, possesses built to software worth on is data.
As it I with is the before, have is simply data not kingdom. said king, AI,
pool as in of platform. more expansion algorithm outcome as our imaging breast prediction deep be generate in Our connectivity we AI One leap detection comprehensive yet quantum combined data, anticipate to clinical XXXX. will a accessible team, AI a will of capability ProFound detection, world-class with emerging addition capability our capability our significant another in and
these I our We remain and past. many to active in which leading PACS now drive the towards players PACS take in I'd have like highlighted to a to moment discussions very with partner discuss the relationships. formalizing continue strategy of
Aligning our complexity rapidly the SaaS-based as evolving, well. companies, a evolving is that as images than revenue cloud, Just ability cloud architectures, and to software-intensive have transport user of their technology PACS and mammography platforms. interfaces, hardware is with higher computing capture, level in rapidly of design inherent archive models associated
solution on-demand are will utility time anywhere, Although then agreements predictability as look these ahead. access, recurring seamless complex we pay-per-use revenue result anytime, and and even AI greater with revenue intensive, be clinical significant the more
partners be direct sales emerges both channel model this PACS channel as in an our partners. potent distribution that obvious complement increasingly XXXX and OEM We an our transparency full provide and will will and believe beyond. We to
Europe. to on Moving
new prominent We cover the I distributor, already countries new distributors. XX SAOK this Italian expanding third our added in are will AI our X imaging market. distributors quarter, We now XX companies Republic highlight with that that most with market. the the would Austria. and Italy, the footprint only works Czech we In largest [ph], in cover and
very So we pleased them to a on partner. board are distribution have as
continue will We our capability, building distribution OUS.
Taiwan, and we in Belgium. Greece, quarter, first Austria, third the Malaysia our in Also sales completed
in to very tomosynthesis are large U.S. the opportunity, pleased where with sales remain CAD XD in of significantly currently Europe, is adoption phase relative We XD our the market while momentum a earlier
breast most our than investors population the remind among Mark that as European with burden, AI cancer women. market cancer received for CE for global We more approval iCAD This an for the XD accounts cancer mammography common Europe. the recently of important XX% is in European ProFound
are adoption early and still ProFound deepening while cancer we to towards breast work While of about are AI growth the continues we in rather encouraged detection. encouraged iCAD -- capabilities we currently cycle, our in are believe
we emerge and Specifically, they continue cancers that tools take be above, to develop allow as referenced predict action. able before breast will to appropriate our to customers
screening We the risk-adaptive clearly see emergence screening is of being from an increasingly model. called what age-based
more with Our towards efforts frequent and more patient are emerging concerning and with for profiles. with more screening, screening higher personalized women aligned well risk individualized the trend
the we the prediction to ProFound also So on product only next-generation the available will a risk with of market for sophisticated characteristics likely commercially and first remain with the AI equally predictive have on cancer analysis will image highly focused we incorporate combined in of we also in believe a genomic data. ahead individual product detection XXXX. market intend in a We and level breast while cancers, remain
previously our highlighted in cases over data. X with years Karolinska along us the agreement with This Sweden. risk agreement prestigious of XX,XXX exclusive Recall, genomic Institute with access to gives characterization
a this this project provide North thorough the will December. at America more We update Chicago, Radiological on in early held Conference, Society of
Xoft and Let's business. about gears our talk switch
sources certain on cycles. longer -- and on software this -- recurring per are As contracts, can used closing deals our those equipment we applicators x-ray Xoft and fact performance. impact is radiation basis. quarter-to-quarter indication Xoft's X/X have a have The disposables are lumpy, significant past for treatment revenues recurring per of our past, in size shipments Capital and the be quarter. can also therapy Tempering revenues experienced or revenues or of what discussed revenue, our timing most and the we rather is quite on this that a per that are purchase service a cycles are this and than
steady sales the For several are cancer resulting we yet discuss new presented and the second of since in over as half will line been new XXXX quarters, sales reasons QX, to momentum applicators indications introduced. be in increased anticipate state to of our for have I continue Therapy next
FDA-cleared and financing prostate rectal, based initiating on is and that trials already cancers. funding was our offerings clinical in underway. Recall effort This QX for brain
date. several important adoption. months within yet also of driver of the of very follow-up are breast a future to data IORT the cases number new is This on largest with period longest of We and
oncology on the on financing about from model only June. proposed we We we radiation We saw in payment In spoke codes completed July, spite prospect in the their hesitancy some CMS. total when upside for can QX in of at codes the of business, being codes codes around CMS. potential believe however, that the calculate customers final that operation. speculate introduced proposed the has market the calls the the therapy of the timing Xoft of the our resulted on of In for issuance uncertainty radiation these details represent length newly and these quarterly changes our significant from we the proposed impact proposed as
clear and to single-treatment proposed technology. CMS of codes tenet is and volume quality is over a very of care focus This and focus advantageous of value quantity a the represent potentially tenet the care. this basic on This IORT codes.
To XX% IORT codes, XX% that new restate propose of about the This -- XX,XXX CMS indeed likely would in more by past this oncology includes sites The under payment July. remain the did would what radiation old individuals. model. cover remaining codes, existing we breast proposal new specifically of payment bundled areas a sites populated than know the Xoft
the the that April that mid-September. of we now indicated either close or of are time is months from for frame CMS that notifications in likely XXXX possible implementation in commentary several would of plan consultants, more ahead and/or final ended our issuance with may in period beyond QX of QX a inside implementation industry XXXX XX-day commencement others and of The January XXXX. The We CMS about be to the judgment now learn that. July experts
updates and rest as We as radiation clarity treating the is well the as sites. guidance, CMS are therapy looking from for of further community
be radiation As continues to further and than to us the to in increase therapy uncertainty. continue more CMS second mature. clarity are applicator we controller although reluctant challenged lack current previously make steady stated, volume customers from about The project in as clinical the trials quarters, potential of of and Xoft several guidance XXXX encouraged many state next the for by this half revenues both
new X introduced for brain cancer the investing XXXX, the our applicators in we and codes indication. implemented. being are fully particularly indications stated that XXXX, being rectal, consistent in allow prostate while would to volume, long appropriately continue activities items chosen levels Correspondingly, Of this and accelerate commercial intrigued carefully when to cancer pace and we modestly us long-term that prostate at sales at opportunity anticipated lead-time with the are in investments
suite already as surgical evaluating same the surgery, course during Xoft robotic one-and-done is potentially course As with potentially underway. a A even of therapy weeks therapy prostatectomies, incorporated and delivering believe prostate treatment is delivered that to are radiation prostate of testing Florida. care. Hospital versus in traditional still surgical where a simultaneous surgery technology This feasibility during therapy radiation the category perform accompanying of a surgery We used The treatment project cancer entirely and IORT of non-shielded reminder, concept non-shielded an radiation of deliver follow-up room radiation minutes on-demand prostate in robotic in to with intraoperative category Celebration during new at we represents the in thereby in combining the for use is Xoft conducted concept real-time, technology, robotic cancer patient robotic suite. the so cancer. radiation the X-day, We've breast do into surgical on-demand now IORT, surgical procedures we the portable therapy while itself. initial of is
XX% prostate As radical prostate I our care rather, -- see elements category radiation the on from prostatectomy have XXXX. in cancer. this for benefit last patients Xoft's clinical therapy call, look XX% much the this for to impact potential robotic mature of of surgeons, study to of it surveyed but indication significant, new we top as according as We intraoperative as could will offering will catch said
paced in with as applicators, our investments measured we XXXX. XXXX and prostate So anticipate mentioned, properly just continuing and in
that new indications these cancer new will to already expanded Xoft cleared. trials involve indications for and post-market dramatically are of FDA All
just may kept best in lumpectomy IORT Imagine, treatment. reconstruction. secret the day of cancer the believe breast care, the current We capability, secret women's and codes, combined breast be radiation or uncertainty timing kept the in Xoft's that minutes also single with accompanied XX real-time even certainly, with new a best health on therapy of breast by reimbursement
equivalent learn about option. It's time option clear an shows and all It's many of chosen that weeks to women has women that of thousands this therapy. that treatment have radiation data
in as to weeks and and follow-up is proven years it data. and this radiation option hear All and be Our for And goal which become need aware technology, available. months as woman ahead about that therapy. know is of is treatment every exists it's of traditional to very now women FDA the cleared the many to has effective of
public for IORT for underway relations in-house part is Xoft. both iCAD with is awareness a built-out, thrust that our now significant Building of now newly team public relations and
had awareness more In exposure this already in breast in fact, month, the company's history. we've than media month, cancer quarter any
this and know, cancer to the treatment a excellent this clinical all and coverage know has about for Patients in media countries IORT of XX All The technology study has exposure type example, dozen over women a Medtech with We and single have clinicians and readership have an right obligation breast Ways available Medical Cancer, MDDI, from right months Let print a has studies a direct that Battling the extensive and industry, this option. treatment significantly The entire clinical ago, for example have of and IORT October very positive and their It to featured XX article, #X. publication. been Is XX. in well do patients to just online years me to outcomes been upfront right is X Diagnostic an viable Vanderbilt at to many vetted, conclude worldwide. as anticipate come. October Xoft's author is Device Breast is of also more constituencies. entitled, we widely highlighted distributed University. days highlights data
the a now can financial call so provide will more review to turn results. comprehensive over Scott, our he of I
